The market for psychedelic drugs to treat mental health conditions gets a big buy signal - CNBC

What the report says

CNBC reported that Eli Lilly’s planned purchase of AtaiBeckley, a clinical-stage psychedelic drug developer, for as much as $3.8 billion is being viewed as another sign that major pharmaceutical companies are moving closer to a field long associated with stigma and legal restrictions. The deal, announced Thursday, centers on potential treatments for mental health conditions where existing medicines do not work for many patients.

According to CNBC, AtaiBeckley’s main program is BPL-003, an intranasal synthetic version of 5-MeO-DMT, a compound linked to Sonoran Desert toad venom, being tested for treatment-resistant depression. The company has reported Phase 2b results showing rapid and lasting symptom reductions, and the drug has FDA Breakthrough Therapy Designation and is now in Phase 3 trials. CNBC cited Jefferies analysts who said successful late-stage results by early 2029 could create a $1 billion to $2 billion opportunity in that indication.

The article placed the acquisition within a broader revival of research into substances such as LSD, psilocybin, MDMA, ayahuasca and ibogaine for depression, PTSD, anxiety, eating disorders and addiction. CNBC noted that the field has also faced setbacks, including the FDA’s 2024 rejection of an MDMA-assisted PTSD therapy from Lykos Therapeutics, while other companies have reported encouraging trial data.

CNBC also pointed to Johnson & Johnson’s Spravato, an esketamine nasal spray, as the most commercially advanced example of an alternative psychiatric drug, with sales projected by analysts to top $2 billion this year. Remaining barriers include FDA review, federal and state drug scheduling, insurance coverage and payment negotiations.